This website is now the new JPND's archival platform. This website hosts all of JPND's archived content and resources.
Please continue to visit this site to access publications, videos and reports from JPND's activities.
Enhancing capacity of neuroimaging and biomarkers- application in early stage Alzheimer’s disease with co-morbidities Investments < €500k Bulgaria 2016
Characterizing the Role of the Endosomal/ Lysosomal system in beta-Amyloid Production and Secretion in Alzheimer’s disease Investments < €500k Canada 2016
Synapse formation, synaptic plasticity and neurodegeneration: The role of MEN1 gene Investments < €500k Canada 2016
Alzheimer treatment based on the editing of the Amyloid Precursor Protein gene Investments < €500k Canada 2016
AD ontological architecture for neuroimaging datawarehouse: merging and establishing anatomical normative data from 17 datasets Investments < €500k Canada 2016
CBRAIN: A national platform for neurodegenerative disease imaging data Investments < €500k Canada 2016
Regulation of Metabotropic Glutamate Receptor Scaffolded Signaling Complexes Investments < €500k Canada 2016
The contribution of extracellular tau to the propagation of neurodegeneration in Alzheimer disease Investments < €500k Canada 2016
Long-term stability of local field potentials recorded from the subthalamic nucleus and effects of deep brain stimulation Investments < €500k Canada 2016
Mechanisms of amyloid-beta clearance in models of vascular cognitive impairment and mixed dementia Investments < €500k Canada 2016
The contribution of extracellular tau to the propagation of neurodegeneration in Alzheimer disease Investments < €500k Canada 2016
Neural stem cells and the promotion of healthy brain aging Investments < €500k Canada 2016
Neuropsychological Functioning of Women with Prophylactic Oophorectomy Investments < €500k Canada 2016
A Defined Abeta Oligomer Epitope: Theranostic Applications Investments < €500k Canada 2016
Neural stem cells and the promotion of healthy brain aging Investments < €500k Canada 2016
Imaging-genetics biomarkers for disease risk in Alzheimer’s Disease. Investments < €500k Canada 2016
Developing a Novel Neuroprotective Drug Target for Alzheimer’s Disease Investments < €500k Australia 2016
Tau protein and insulin signaling pathways: implication to Alzheimer’s disease and diabetes Investments < €500k Australia 2016
Therapeutic Intervention in Alzheimer’s Disease; Intranasal Oxytocin Administration to Enhance Emotion Processing and Reduce Caregiver Burden Investments < €500k Australia 2016
Imaging the eye to diagnose pre-clinical Alzheimer’s Disease Investments < €500k Australia 2016
De stem van ons (The Voice of Our Memory) Investments < €500k Belgium 2016
AD Immunotherapy : Towards a disease modification therapy in Alzheimer disease via targeting Tau protein with monoclonal antibodies Investments < €500k Belgium 2016
Follow.Me Investments < €500k Belgium 2016
Haalbaarheidsstudie van de eerste pijplijnproducten van Thera Neuropharma NV voor de behandeling van amytrofe laterale sclerose en traumatische hersenletsels (Feasibility study of the first pipeline products Thera Neuro Pharma NV for the treatment of amyotrophic lateral sclerosis and traumatic brain…
Mechanisms of neurodegeneration caused by peroxisomal beta-oxidation deficiency Investments < €500k Belgium 2016
Amyloid Beta and sleep problems, a neurotoxic pas de deux during aging? Investments < €500k Belgium 2016
Neuro Image-guided decoding of mechanisms involved in healthy, accelerated and pathological aging Investments < €500k Belgium 2016
Mitochondrial imaging in live neurons from Parkinsons disease patients Investments < €500k Belgium 2016
Functional parameters that depend on prefrontal cortex and hippocampus in mouse Alzheimer’s disease models and their use to evaluate experimental therapies Investments < €500k Belgium 2016
Genetic mosaicism in the brain as a cause of Alzheimer’s Disease Investments < €500k Belgium 2016
Deconstructing the function of APP as a Wnt signaling receptor and its relevance to Alzheimer’s disease Investments < €500k Belgium 2016
Unraveling molecular pathways underlying synergistic cellular toxicity of Aß peptides and protein Tau, the two key players involved in Alzheimer’s disease. Investments < €500k Belgium 2016
VitaminK2 as a mitochondrial electron carrier to improve Parkinson related deficiency Investments < €500k Belgium 2016
Mechanisms of postural instability in Parkinsons disease: behavioral and neural correlates. Investments < €500k Belgium 2016
Dissecting the role of Parkinson’s Disease related genes in the regulation of clock neurons and circadian rhythms. Investments < €500k Belgium 2016
Selective dopaminergic reward signals in the visual cortex of monkeys, humans en Parkinson patients. Investments < €500k Belgium 2016
Investigating the efficacy of an online intervention aiming to increase respite use amongst carers of people with dementia: Roles of motivational enhancement and professional delivery Investments < €500k Australia 2016
How do people with and without dementia use anticoagulants? Systematic literature review and analyses of PBS data Investments < €500k Australia 2016
“Beauty and the brain” – A novel approach to anhedonia in dementia Investments < €500k Australia 2016
A novel neuroprotective mechanism in Alzheimer’s disease Investments < €500k Australia 2016
Does social competence impact quality of life for people with a diagnosis of dementia? Investments < €500k Australia 2016
The neural correlates of memory improvement following transcranial direct current stimulation combined with cognitive training Investments < €500k Australia 2016
The development and evaluation of an educational program for the care of older people with dementia in emergency departments Investments < €500k Australia 2016
Meeting the support needs of family carers of people living with dementia in the community: Potential translation into practice Investments < €500k Australia 2016
Neuroinflammation in frontotemporal dementia: The role of microglia in TDP-43-related disease Investments < €500k Australia 2016
The inflammatory mediator Lactorferrin induces rapid and pronounced amyloidogenic processing of APP Investments < €500k Australia 2016
Development of staging criteria to distinguish preclinical tauopathies from primary age-related tauopathy (PART) Investments < €500k Australia 2016
The development and trial of an innovative community based Respite Action intervention for carers of people with Dementia Investments < €500k Australia 2016
DOGS+CELLS Trial Investments < €500k Australia 2016
Ubiquitinomic Profiling of synaptic proteins in Alzheimer’s Disease Investments < €500k Australia 2016
